TLX
Telix Pharmaceuticals Limited · Healthcare
9.09
0.44%(-0.04)
Prev. Close9.90
8.91%(+0.81)
Pre-marketLast Updated: — ET
52W L: $6.2852W H: $20.00
$9.69
CHG+2.38 (+32.56%)
H$10.00
L$7.20
VOL3.6M
TLX (1h)
TLX NEWS
globenewswire.com
16h ago
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
defenseworld.net
1d ago
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts
Telix Pharmaceuticals Limited (NASDAQ: TLX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and
globenewswire.com
5d ago
Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.
globenewswire.com
Mar 20
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies (RLS) sites in the United States (U.S.).
globenewswire.com
Mar 20
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
Louvain‑la‑Neuve, Belgique, le 20 mars 2026 - IBA (Ion Beam Applications S. A. , EURONEXT), leader mondial des technologies d'accélérateurs de particules et premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce la signature d'un contrat avec Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), entreprise d'oncologie de précision, pour une première commande de quatre cyclotrons Cyclone KIUBE aux conditions standards d'IBA1.
seekingalpha.com
Mar 17
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript